About: Tocilizumab for severe COVID‐19 pneumonia: Case series of 5 Australian patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Tocilizumab for severe COVID‐19 pneumonia: Case series of 5 Australian patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Tocilizumab for severe COVID‐19 pneumonia: Case series of 5 Australian patients
Creator	David, \| Tran, Tuan Ltd, Wiley, John Australia, Sons Cannon, Christine Chan, Kevin Cheong, Elaine Cheong, Sai Cheung, Winston Choudhury, \| Claude, \| Deepak Bhonagiri, \| Farah, S Fernando, Shelanah Frankum, \| Kanapathipillai, Rupa Karuna Keat, \| Kol, \| Malik, Sameer Murfin, Brendan Nalpantidis, Anastasios Naqvi, \| Ojaimi, \| Riminton, Sean Shah, Asim Wagh, Atul Wan, Jenny West, Timothy
source	PMC
abstract	AIM: To describe the first Australian cases of severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV2) disease (COVID‐19) pneumonia treated with the interleukin‐6 receptor antagonist tocilizumab. METHODS: Retrospective, open‐label, real‐world, uncontrolled, single‐arm case series conducted in 2 tertiary hospitals in NSW, Australia and 1 tertiary hospital in Victoria, Australia. Five adult male patients aged between 46 and 74 years with type 1 respiratory failure due to COVID‐19 pneumonia requiring intensive care unit (ICU) admission and biochemical evidence of systemic hyperinflammation (C‐reactive protein greater than 100 mg/L; ferritin greater than 700 μg/L) were administered variable‐dose tocilizumab. RESULTS: At between 13 and 26 days follow‐up, all patients are alive and have been discharged from ICU. Two patients have been discharged home. Two patients avoided endotracheal intubation. Oxygen therapy has been ceased in three patients. Four adverse events potentially associated with tocilizumab therapy occurred in three patients: ventilator‐associated pneumonia, bacteremia associated with central venous catheterization, myositis and hepatitis. All patients received broad‐spectrum antibiotics, 4 received corticosteroids and 2 received both lopinavir/ritonavir and hydroxychloroquine. The time from first tocilizumab administration to improvement in ventilation, defined as a 25% reduction in fraction of inspired oxygen required to maintain peripheral oxygen saturation greater than 92%, ranged from 7 hours to 4.6 days. CONCLUSIONS: Tocilizumab use was associated with favorable clinical outcome in our patients. We recommend tocilizumab be included in randomized controlled trials of treatment for patients with severe COVID‐19 pneumonia, and be considered for compassionate use in such patients pending the results of these trials.
has issue date	2020-08-13(xsd:dateTime)
bibo:doi	10.1111/1756-185x.13913
has license	no-cc
sha1sum (hex)	14657d906a836a6534b924218f1e1c783dc53469
schema:url	https://doi.org/10.1111/1756-185x.13913
resource representing a document's title	Tocilizumab for severe COVID‐19 pneumonia: Case series of 5 Australian patients
has PubMed Central identifier	PMC7436606
schema:publication	Int J Rheum Dis
resource representing a document's body	covid:14657d906a836a6534b924218f1e1c783dc53469#body_text
is schema:about of	named entity 'pneumonia' named entity 'disease' named entity 'Tocilizumab' named entity 'peer-reviewed' named entity 'type 1 respiratory failure' named entity 'tocilizumab' named entity 'Noradrenaline' named entity 'tocilizumab' named entity 'CAR' named entity 'D-dimer' named entity 'tocilizumab' named entity 'ferritin' named entity 'IL-6' named entity 'CAR T-cell therapy' named entity 'Therapeutic Goods Administration' named entity 'tocilizumab' named entity 'coronavirus' named entity 'interleukin-6' named entity 'SpO2' named entity 'mechanically ventilated' named entity 'preprint server' named entity 'COVID' named entity 'radiographic' named entity 'patient-years' named entity 'continuous positive airway pressure' named entity 'animal studies' named entity 'biochemical' named entity 'COVID' named entity 'juvenile idiopathic arthritis' named entity 'hydroxychloroquine' named entity 'tocilizumab' named entity 'fever' named entity 'tocilizumab' named entity 'interleukin-6' named entity 'COVID' named entity 'peer review' named entity 'tocilizumab' named entity 'FiO2' named entity 'respiratory failure' named entity 'immunomodulation' named entity 'CRP' named entity 'phase 2' named entity 'mm Hg' named entity 'mm Hg' named entity 'FiO2' named entity 'tocilizumab' named entity 'PaO2' named entity 'COVID-19' named entity 'Coronavirus disease 2019' named entity 'pneumonia' named entity 'endotracheal intubation' named entity 'oxygen therapy' named entity 'tocilizumab' named entity 'rheumatoid arthritis' named entity 'tocilizumab'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software